A study to see the efficacy of dextrose prolotherapy in sacroiliac joint pain.

Efficacy and durability of dextrose prolotherapy pain management of chronic sacroiliac joint pain assessed by Ronald Moris Disability Questionnaire and Numeric Rating Score

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2017/08/009263

Enrollment

Registered

2017-08-04

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: M538- Other specified dorsopathies

Interventions

Intervention1: 12.5% Dextrose with 0.25% Bupoivacaine: It will be given intra articular sacroiliac joint under fluroscopic guidance. Control Intervention1: Nil: NA

Eligibility

Inclusion criteria

Inclusion criteria: Patients having signs and symptoms of sacro-iliac joint pain. Patients having pain for more than 6 months. Patients undergoing conventional therapy but not iterventional therapy.

Exclusion criteria

Exclusion criteria: Pregnancy Inflamatory disease Infection or cellulitis Peripheral nerve disease Unhealed fractures or other debilitating diseases. Cancer

Design outcomes

Primary

Measure	Time frame
Pain in Neumaric Rating Scale (NRS) scoreTimepoint: At day 0, after 2 weeks, 4 weeks and 3 months after last injection	—

Secondary

Measure	Time frame
Roland Moris Disability Questionnaire (RMDQ) scoreTimepoint: At day 0, after 2 weeks, 4 weeks and 3 months after last injection	—

Countries

India

Contacts

Public ContactDr Subrata Goswami

ESI Institute of Pain Management

drsgoswami@gmail.com9830430430

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026